Scleroderma Lung Disease

被引:30
作者
Le Pavec, Jerome [1 ,2 ]
Launay, David [3 ]
Mathai, Stephen C. [2 ]
Hassoun, Paul M. [2 ]
Humbert, Marc [1 ]
机构
[1] Univ Paris 11, Hop Antoine Beclere, Serv Pneumol & Reanimat Resp, Ctr Natl Reference Hypertens Arterielle Pulm,AP H, F-92140 Clamart, France
[2] Div Pulm & Crit Care Med, Baltimore, MD 21205 USA
[3] Univ Lille 2, Ctr Reference Sclerodermie Syst, Serv Med Interne, Hop Claude Huriez, Lille, France
关键词
Scleroderma; Scleroderma lung disease; Pulmonary arterial hypertension; Interstitial lung disease; Scleroderma-related pulmonary arterial hypertension; PULMONARY ARTERIAL-HYPERTENSION; PROGRESSIVE SYSTEMIC-SCLEROSIS; CONNECTIVE-TISSUE-DISEASE; CONTINUOUS INTRAVENOUS EPOPROSTENOL; NONSPECIFIC INTERSTITIAL PNEUMONIA; RESOLUTION COMPUTED-TOMOGRAPHY; DIFFUSE CUTANEOUS INVOLVEMENT; POPULATION-BASED COHORT; RIGHT HEART FUNCTION; FIBROSING ALVEOLITIS;
D O I
10.1007/s12016-009-8194-2
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Pulmonary involvement is second in frequency only to esophageal involvement as a visceral complication of systemic sclerosis (SSc) and has surpassed renal involvement as the most common cause of death. Interstitial lung disease and pulmonary vascular disease, particularly pulmonary arterial hypertension, are the most commonly encountered types of lung involvement. Chronic aspiration, airway disease, neuromuscular weakness, extrinsic pulmonary restrictive pathology, pleural effusions, pneumothorax, and lung cancer cause clinically significant disease and occur commonly enough to be routinely considered in the assessment of the SSc patient with respiratory symptoms. Affected patients have a significantly worse prognosis than patients with SSc who are free of pulmonary involvement.
引用
收藏
页码:104 / 116
页数:13
相关论文
共 153 条
  • [1] LUNG-FUNCTION ABNORMALITIES AND DECLINE OF SPIROMETRY IN SCLERODERMA - AN OVERRATED DANGER
    ABRAMSON, MJ
    BARNETT, AJ
    LITTLEJOHN, GO
    SMITH, MM
    HALL, S
    [J]. POSTGRADUATE MEDICAL JOURNAL, 1991, 67 (789) : 632 - 637
  • [2] Airò P, 2004, CLIN EXP RHEUMATOL, V22, P573
  • [3] IMPROVED PULMONARY-FUNCTION IN SYSTEMIC-SCLEROSIS AFTER TREATMENT WITH CYCLOPHOSPHAMIDE
    AKESSON, A
    SCHEJA, A
    LUNDIN, A
    WOLLHEIM, FA
    [J]. ARTHRITIS AND RHEUMATISM, 1994, 37 (05): : 729 - 735
  • [4] Al-Dhaher FF., 2008, SEMIN ARTHRITIS RHEU
  • [5] ALSABBAGH MR, 1989, J RHEUMATOL, V16, P1038
  • [6] PREDICTORS OF SURVIVAL IN SYSTEMIC-SCLEROSIS (SCLERODERMA)
    ALTMAN, RD
    MEDSGER, TA
    BLOCH, DA
    MICHEL, BA
    [J]. ARTHRITIS AND RHEUMATISM, 1991, 34 (04): : 403 - 413
  • [7] ALTON E, 1988, LUNG INVOLVEMENT SCL
  • [8] [Anonymous], 1990, Am Rev Respir Dis, V141, pS169
  • [9] Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis
    Apras, S
    Ertenli, I
    Ozbalkan, Z
    Kiraz, S
    Ozturk, MA
    Haznedaroglu, IC
    Çobankara, V
    Pay, S
    Calguneri, M
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (08): : 2256 - 2261
  • [10] Badesch DB, 2007, J RHEUMATOL, V34, P2417